Regulation
Federal Cannabis Legalization: Goals, Barriers & Solutions
Add MyCannabis.com to your preferred sources on Google
Federal cannabis reform involves several separate decisions: which activities are lawful, how products are regulated, what happens to past convictions, and how businesses are taxed. Changing a drug’s schedule addresses only part of that framework.
New Frontier Data and Verde Compliance Partners released Federal Cannabis Policy: Facilitating Successful Regulation in August 2022. The report identified four objectives: reducing illicit trade, protecting public health, addressing unequal enforcement, and supporting employment and tax revenue. Those are policy goals, not evidence that any particular reform has already achieved them.
What Federal Rescheduling Has Changed
A federal rule effective April 28, 2026 placed FDA-approved marijuana drug products and marijuana subject to qualifying state medical marijuana licenses in Schedule III. Other marijuana remains in Schedule I. The rule also established an expedited federal registration process for state medical license holders and retained controls on authorized activities, imports, and exports.
This is a significant medical-market change, but it does not create nationwide adult-use legalization. A state license, a federal registration, and FDA approval answer different questions. The medical rescheduling rule should not be read as blanket permission for every dispensary product, recreational sale, or interstate shipment.
Four Goals and How to Assess Progress
The report’s four objectives provide a framework for evaluating policy through measurable outcomes.
| Objective | Policy challenge | Useful measures |
|---|---|---|
| Reduce illicit trade | Make authorized supply accessible while enforcing rules against unauthorized sellers. | Consumer sourcing, prices, retailer access, and consistent estimates of unauthorized activity. |
| Protect health and safety | Connect product standards with enforcement and consumer education. | Contamination findings, recalls, accidental exposures, and adverse-event reporting. |
| Address unequal enforcement | Provide effective relief for eligible past offenses and assess ongoing disparities. | Records cleared, processing times, arrest rates, and outcomes across communities. |
| Support jobs and public revenue | Create viable businesses while funding oversight and public services. | Employment, business survival, collected revenue, and regulatory costs. |
Diminishing the Illicit Market
A legal market must offer a practical route for both consumers and compliant businesses. Our assessment is that licensing design, retail access, total purchase prices, and enforcement should be evaluated together. A license program can exist on paper while consumers still face long travel distances or few authorized choices.
The original report discussed ways to help participants enter regulated commerce, including training and changes to financing and tax policy. These remain proposals to evaluate, not a basis for promising an SBA loan to a particular cannabis business. Eligibility depends on the actual program and applicable law.
Market estimates also need a defined year and method. An old estimate of illicit spending in one state cannot establish the size of today’s national market. Likewise, increased legal sales do not, by themselves, show an equal decline in unauthorized sales: population, prices, and consumption can change at the same time.
Improving Public Health and Safety
The EVALI outbreak illustrates why product oversight matters. It began in 2019; the CDC’s February 2020 outbreak summary recorded 2,807 hospitalized cases or deaths and 68 confirmed deaths. THC-containing vaping products, especially those obtained from informal sources, played a major role. Vitamin E acetate was strongly linked to the outbreak, although other contributing chemicals could not be ruled out.
Those historical figures should not be described as a new 2020 outbreak or a current annual death count. They also do not establish that all regulated products are harmless. Testing, traceability, recalls, and clear labeling serve different purposes and need effective implementation.
For evaluating reform, we would look beyond the number of licenses issued. Are contaminated batches identified and removed? Can consumers understand product strength and warnings? Are accidental exposures and other adverse events measured consistently? These questions connect regulation to outcomes that matter to the public.
Addressing Past Convictions and Unequal Enforcement
The ACLU’s 2020 analysis, covering arrests from 2010 through 2018, reported that Black people were 3.64 times as likely as white people to be arrested for marijuana possession despite similar use rates. That is a finding from a specified historical dataset, not a verified nationwide arrest ratio for 2026.
Relief also has to be described accurately. The Justice Department explains that a presidential pardon does not erase or expunge a conviction. A federal pardon does not replace the processes that apply to state convictions. Rescheduling, pardoning, sealing, and expungement are distinct actions.
Our assessment is that a reform program should be judged partly by whether eligible people actually receive relief. Application costs, incomplete records, and processing delays can matter as much as the language announcing a program. Counting completed relief and its practical effects is more informative than counting announcements alone.
Taxes, Banking, and Business Viability
Internal Revenue Code Section 280E denies deductions or credits for businesses trafficking in Schedule I or II controlled substances in violation of federal or state law. Its wording does not extend that restriction to Schedule III substances. The medical rescheduling change therefore matters for tax treatment, while adult-use activity involving Schedule I marijuana remains a separate issue. It is inaccurate to say that Section 280E has been repealed for the entire industry.
Mixed medical and adult-use operations need to evaluate their actual activities and applicable tax guidance. A policy announcement should not be treated as an automatic entitlement to refunds for earlier years.
Banking access is another separate question. FinCEN’s marijuana-business guidance describes customer due diligence and suspicious activity reporting, while leaving account decisions to financial institutions based on their circumstances and risk assessments. It is not a guarantee that a bank will accept a business or provide affordable credit.
Older projections of one million jobs by 2025 or a particular market value in 2030 should not be presented as achieved results. A useful economic assessment identifies the reporting year, separates forecasts from observed data, and considers business closures, wages, tax collections, and the cost of regulation.
What Successful Reform Would Require
The 2022 report offers a useful set of objectives, but evaluating reform requires more than checking whether marijuana has moved between schedules. The practical questions are whether lawful access works, unsafe products are addressed, eligible people receive meaningful relief, and businesses can operate within a clear framework.
Medical rescheduling should be assessed on its actual scope. Broader adult-use legalization and the design of a national commercial market require their own legal changes. Keeping those distinctions clear makes both policy debate and business planning more reliable.
